-
-
Steady Start to 2022; FY 2022 Constant Currency Revenue Growth Guidance Reaffirmed
BOSTON, United States and LAUSANNE, Switzerland, May 10, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2022.
Recent Highlights
- Revenue for the first quarter of 2022 was $10.9 million, representing year-over-year revenue growth of 21%
- Constant currency revenue growth excluding COVID-19-related revenues was 35%, attributable to strong platform analysis volume growth
- SOPHiA GENETICS’ expectation of 30% to 35% constant currency revenue growth for full-year 2022 remains unchanged; reported revenue growth guidance has been updated for strengthening of U.S. dollar
- Total genomic profiles analyzed to date on the SOPHiA DDM platform has exceeded 1,000,000
- Total recurring platform customers grew to 384 as of March 31, 2022 up from 345 as of March 31, 2021
-